Quarterly ResultMay 13, 2026, 04:14 PM
Insight Molecular Diagnostics Reports Q1 2026 Results; GraftAssureDx Commercialization Progresses
AI Summary
Insight Molecular Diagnostics Inc. reported Q1 2026 revenues of $32,000 and a net loss of $4.3 million, or $0.12 per share, as the company remains pre-revenue for its kitted diagnostic products. The company is making significant progress toward commercializing its GraftAssureDx kidney transplant monitoring assay, including productive dialogue with the FDA for marketing authorization expected later in 2026. Additionally, iMDx secured its first clinical trial agreement for the GALACTIC registry study with a major U.S. transplant center and saw initial research-use-only kit purchases outside the U.S.
Key Highlights
- Q1 2026 revenue was $32,000, derived solely from laboratory services.
- Q1 2026 net loss was $4.3 million, or $0.12 per share.
- Operating expenses for Q1 2026 were $4.4 million, including a $5.9 million non-cash gain from contingent consideration.
- Cash, cash equivalents, and restricted cash stood at $29.4 million at the end of Q1 2026.
- Net cash used in operating activities was $7.6 million in Q1 2026.
- Signed first clinical trial agreement for GALACTIC study with a Northeast kidney transplant center (among top 10 in U.S.).
- Productive dialogue with FDA supports expected GraftAssureDx marketing authorization later in 2026.
- Booked research-use-only purchase by an E.U. transplant center, with another APAC purchase expected soon.